Subjects successfully completing the dose titration phase ( n = 177 ) ( ie , tolerated and responded to treatment and adhered to the protocol ) were randomized to receive 2 weeks ' treatment with their individualized dosage of OROS methylphenidate ( 18 , 36 , 54 , or 72 mg once daily ) or placebo .
